No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

Target·Modality

Indication

Stage

Deal Value

(USD Mn)

1

7/1

Merck

Orion

Small molecule

(opevesostat, Oral route)

CYP11A1

Hormone-Sensitive Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase III

1630

2

7/1

Yuhan

Ubix Therapeutics

Small molecule

(UBX-103)

Androgen Receptor

Prostate Cancer

Preclinical

108.6

3

7/3

GSK

Curevac

mRNA Vaccine

(GSK-4396687A, Intramuscular route)

2019 Novel corona Virus Spike Glycoprotein

Infectious Disease, COVID-19

Phase II

1556.18

4

7/11

Ipsen

Foreseen

Monoclonal Antibody Conjugated

(FS-001)

DNA Topoisomerase I

Solid Tumor

Preclinical

1030

5

7/16

Vertex Pharmaceuticals

Orum Therapeutics

Dual-Precision Targeted Protein Degradation (TPD²®) technology

n/d

gene editing

-

Discovery

335

6

7/16

SOTIO Biotech

Biocytogen Pharmaceuticals

RenLite platform,

ADC platform

n/d

Solid Tumor

Discovery

325.5

7

7/17

SK Biopharmaceuticals

Full-Life Technologies

Synthetic Peptide

(FL-091)

Neurotensin Receptor Type 1

Pancreatic Cancer, Sarcomas, Head And Neck Squamous Cell Carcinoma (HNSC)

Preclinical

571.50

8

7/24

Novartis

Dren Bio

Monoclonal Antibodies

for Solid Tumors

n/d

are developed using proprietary targeted myeloid engager and phagocytosis platform technology

solid tumor

Discovery

3000

9

7/25

Ipsen

Day One Biopharmaceuticals

Small Molecule

(tovorafenib)

RAF Proto Oncogene Serine/Threonine Protein Kinase

Low-Grade Glioma

Marketed

461

10

7/31

Ideaya Biosciences

Biocytogen Pharmaceuticals

Bispecific ADC Program

B7H3/PTK7 Topo-I-Payload

Solid Tumor

Discovery

406.5

No.

Date

Acquires

Issuer

주요 파이프라인

금액
(USD Mn)

1

7/8

Eli Lilly

Morphic

(MORF-057) Type : Small Molecule

Target : Integrin Alpha 4, Integrin Beta 7

Indication : Eosinophilic Esophagitis, Ulcerative Colitis, Crohn's Disease (Regional Enteritis)

Stage : Phase II

3200

2

7/29

Boehringer Ingelheim

Nerio Therapeutics

(Allosteric or Uncompetitive Phosphatase Inhibitors)

Type : Small Molecule

Target : tyrosine-protein phosphatase non-receptor type 1 and 2 (PTPN1 and PTPN2)

Indication : unspecified cancer

Stage : Preclinical

1300

3

7/8

Ligand Pharmaceuticals

APEIRON

(dinutuximab beta)

Type : Monoclonal Antibody

Target : Ganglioside GD2, Ewing Sarcoma, Leiomyosarcoma, Neuroblastoma

Indication : Neuroblastoma

Stage : Marketed

100

4

7/29

Collegium Pharmaceutical

Ironshore Therapeutics

(methylphenidate hydrochloride ER)

Type : Small Molecule

Target : Sodium Dependent Dopamine Transporter, Sodium Dependent Noradrenaline Transporter

Indication : Attention Deficit Hyperactivity Disorder (ADHD)

Stage : Marketed

525